SimplicityBio, founded in 2013, develops AI-based algorithms and software for the development of multi-omic signatures and biomarker assessment. Their technology uncovers novel combinations of biomarkers using diverse data streams, enabling biotech and diagnostics developers to discover accurate and robust biomarkers. SimplicityBio aims to become the top provider of customized in-silico solutions, utilizing multiple biomarkers simultaneously. By combining multiple biomarkers and employing machine learning and artificial intelligence techniques, they create diagnostic algorithms that offer meaningful information about the disease state, leading to effective treatment decisions for complex diseases.